Search for: "PFIZER" Results 1341 - 1360 of 4,632
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
31 Oct 2016, 5:01 am by Mark Astarita
According to press reports, the broker admitted that he executed trades based on inside information supplied by a friend at Pfizer who pleaded guilty in May as part of a deal to cooperate with prosecutors.Under a plea agreement, the broker agreed to forfeit almost $386,000 and not appeal any prison sentence of 2-1/2 years or less.Ex-Oppenheimer adviser pleads guilty to U.S. insider trading charges: [read post]
28 Oct 2016, 4:16 am by Dan Harris
Pfizer’s subsequent attempt to re-brand Viagra from the name it was already called in China (伟哥, or “Weige”) to its preferred choice (万艾可, or “Wan’aike”) was doomed from the start, as evidenced by a series of expensive court cases that Pfizer kept losing. [read post]
24 Oct 2016, 2:35 am
 Thus, the first instance judgment on validity was completely upheld.The second part of the judgment, which procedurally disposes of the case (subject to any appeal to the Supreme Court, which Pfizer is reportedly seeking) relates to the refusal to allow Warner-Lambert (the patentee and Pfizer subsidiary) the opportunity to amend claim 3 after the end of the trial. [read post]
19 Oct 2016, 9:58 pm by Patent Docs
Fast forward to this Monday, October 17, 2016, and Pfizer announced that it would begin shipping the Celltrion biosimilar, named INFLECTRA® (infliximab-dyyb), in late November 2016.... [read post]
18 Oct 2016, 7:00 am by Troy Ungerman
The Pharma, Medical & Biotech sector recorded the largest deal of the month with Pfizer’s acquisition of US-based biopharmaceutical company Medivation for US$13.2bn. [read post]
17 Oct 2016, 1:30 pm by Tom Lamb
As regards drug injury lawsuits concerning this melanoma side effect of ED drugs, that litigation began with Viagra cases being filed against Pfizer, the drug company responsible for Viagra. [read post]
13 Oct 2016, 6:50 am by Brian Cordery
Pfizer appealed this finding arguing that the attack on the sufficiency for central neuropathic pain was not articulated by the challengers in sufficient time for Pfizer to be able to deal with it at the trial. [read post]
12 Oct 2016, 8:48 am by Clay Hodges
So Far ED Drug Makers Deny Increased Melanoma Risk Pfizer has denied any increased melanoma risk from taking Viagra. [read post]
5 Oct 2016, 11:44 am by John Suthers
  The claims involved Pfizer’s marketing of the drug for unsafe and potentially dangerous uses. [read post]
5 Oct 2016, 11:44 am by John Suthers
  The claims involved Pfizer’s marketing of the drug for unsafe and potentially dangerous uses. [read post]
5 Oct 2016, 6:38 am by MBettman
In May of this year, drug company giant Pfizer restricted distribution of its products which could be used for this purpose. [read post]
1 Oct 2016, 5:40 am by Lyle Roberts
 The Pfizer case decided by the Second Circuit earlier this year caused some speculation as to whether that court might break with its sister circuits on price maintenance, but this week the Second Circuit firmly endorsed the theory. [read post]
27 Sep 2016, 9:10 am
Panellists from Pfizer, Sandoz GmbH and Taiwan's National Yunlin University debated the global regulatory, substitution and interchangeability issues affecting biosimilars, before giving an overview of relevant patent litigation strategies. [read post]
27 Sep 2016, 5:53 am by Brenda Fulmer
These lawsuits over Viagra’s cancer link are not the first time that Pfizer has been sued over its popular ED drug. [read post]
22 Sep 2016, 5:32 pm
 Pfizer, who this spring obtained FDA approval for its Remicade biosimilar - Inflectra (infliximab-dyyb)- will join the likes of Novartis, Sandoz, Biogen and Amgen on the scene. [read post]
20 Sep 2016, 1:03 am by Vanessa Rieu
Mei-Hsin Wang (National Yunlin University of Science and Technology (TW)) and Bryan Zielinski (Vice-President, Assistant General Counsel, Pfizer (US)) through a number of topics including data exclusivity, substitution and interchangeability, post grant patent challenges and a review of US and European case law. [read post]
12 Sep 2016, 7:12 am by Robert Kraft
On its front-page, the Washington Post reports that Pfizer “has agreed to disclose in its promotional material that narcotic painkillers carry serious risk of addiction — even when used properly — and promised not to promote opioids for unapproved, ‘off-label’ uses such as long-term back pain. [read post]